| Israel | Türkei | Österreich | |
| Whipple-Operation | von $38,500 | von $23,000 | von $45,000 |
| Robotische da Vinci-Prostatektomie | von $24,570 | von $17,000 | von $20,000 |
| Protonenstrahltherapie | von $48,000 | von $70,000 | von $80,000 |
| Lungenkrebsoperation | von $27,500 | von $17,000 | von $42,000 |
| Hyperthermische intraperitoneale Chemotherapie (HIPEC) | von $61,200 | von $22,500 | von $40,000 |
Dr. Pelles Sharon ist am Sourasky Medical Center auf fortschrittliche Adenokarzinom-Behandlungen spezialisiert, einschließlich HIPEC und Immuntherapie.
Leiter der Abteilung für Weichteil- und Knochenonkologie am Sourasky Medical Center – Dr. Merimsky ist auf komplexe Sarkomfälle spezialisiert.
Dr. Sarid ist auf Chemotherapie und Strahlentherapie spezialisiert und verfügt über mehr als 25 Jahre Erfahrung in der Onkologie am führenden israelischen Sourasky (Ichilov) Medical Center.
Dr. Arnon Nagler ist ein international anerkannter Hämatologe und Experte für Knochenmarktransplantationen. Er ist Professor für Medizin an der Universität Tel Aviv. Am Sheba Medical Center ist er emeritierter Direktor der Hämatologie & Knochenmarktransplantation sowie der Nabelschnurblutbank. Er erwarb seinen M.D. an der Hebrew University–Hadassah und einen M.Sc. in Hämatopoese an der Universität Tel Aviv. Seine Postdoc-Ausbildung absolvierte er an der Stanford University. Er ist fachärztlich in Innerer Medizin und Hämatologie anerkannt.
Er verfügt über mehr als 35 Jahre Erfahrung. Er war Pionier allogener Transplantationsprotokolle mit reduzierter Intensität für maligne und nichtmaligne Erkrankungen. Er gründete Israels erste öffentliche Nabelschnurblutbank und führte die ersten Nabelschnurbluttransplantationen des Landes durch.
Er hatte internationale Führungsrollen inne: Vorsitzender und Co‑Vorsitzender der ALWP der EBMT, stellvertretender Vorsitzender und langjähriges Mitglied von EBMT‑Gremien. Er gehörte dem Vorstand von NetCord/EuroCord an und war deren Schatzmeister. Er ist ein gefragter Referent, hat in Fachzeitschriften wie Blood und Leukemia umfangreich publiziert, leitete als Principal Investigator große klinische Studien und übernahm redaktionelle Funktionen. Für Innovation und klinische Exzellenz erhielt er zahlreiche Auszeichnungen.
Adenocarcinoma treatment in Israel is exceptionally safe for international patients due to JCI-accredited facilities and highly specialized oncology teams. Israeli centers report a 90% average success rate for oncology. Specialists focus on precision protocols. They often correct up to 30% of outside diagnoses.
Bookimed Expert Insight: Israeli oncology centers like Sheba and Sourasky serve over 1,500,000 patients every year. This massive patient volume creates a data-rich environment for refining treatment protocols. Our data shows that top clinics often include comprehensive histopathology revisions in their packages. This step is vital because it catches diagnostic errors before treatment begins.
Patient Consensus: Patients note the relief of having complex diagnostic reviews confirm their exact cancer type. Many emphasize that the coordinated support from dedicated international departments makes navigating the hospital system stress-free.
Adenocarcinoma success rates in Israel are among the highest globally. Statistics show an 80% recovery rate for early-stage cases. Major centers report 90% efficiency for advanced or metastatic treatments. Specific conditions like prostate adenocarcinoma show success rates exceeding 95% due to specialized protocols.
Bookimed Expert Insight: Israeli oncology centers like Sheba and Sourasky prioritize histopathology revisions before treatment begins. Data shows that refined diagnostics often lead to more targeted protocols. For example, Dr. Almog Ben Yaacov at Sheba has performed over 200 HIPEC procedures. This high volume in specialized techniques typically correlates with the superior survival outcomes seen in Israeli gastric and colorectal cases.
Patient Consensus: Patients note that getting a second opinion from Israeli specialists is common for complex cases. They often feel more confident after fast consultations that clarify tumor genetics and staging.
Israel's leading oncology centers specialize in treating adenocarcinoma through high-precision surgery and targeted therapies. Facilities like Sheba Medical Center and Sourasky Medical Center provide access to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) and robotic Da Vinci systems. JCI-accredited hospitals in Tel Aviv and Ramat Gan report success rates reaching 90% for oncology cases.
Bookimed Expert Insight: Israeli oncology centers demonstrate a high level of surgical sub-specialization that directly impacts patient outcomes. For instance, packages at Sheba Medical Center for HIPEC include extensive diagnostics like PET/CT and histopathology revisions. This intensive approach ensures treatment precision. While Sourasky Medical Center offers robotic surgery with doctors like Dr. Yossefovitz Ofer, who trained at Memorial Sloan Kettering, bringing elite techniques to local patients.
Patient Consensus: Patients highlight that Israeli centers offer faster enrollment in clinical trials compared to European options. Many note the benefit of getting full genomic sequencing before arrival to access mutation-specific therapies.
Adenocarcinoma diagnosis in Israel involves high-precision imaging and molecular profiling at JCI-accredited centers. Specialists use PET-CT and PET-MRI to detect metastases and determine TNM staging. Facilities like Sheba Medical Center and Sourasky Medical Center integrate genomic testing and liquid biopsies to create personalized oncology protocols.
Bookimed Expert Insight: Israeli oncology centers demonstrate a high diagnostic volume. Sourasky Medical Center treats over 400,000 patients annually. This massive data pool allows clinics to offer rapid turnaround. Some diagnostic packages at Sheba Medical Center include PET/CT and MRI in a single comprehensive screening. This typically helps international patients complete full staging within 3 to 5 days.
Patient Consensus: Patients note that getting genomic profiling and PSMA-PET scans early is vital. They emphasize that Israeli labs integrate these advanced tests seamlessly into the initial staging process.
Adenocarcinoma treatment in Israel involves cutting-edge surgical and systemic therapies tailored to tumor location and genetics. Patients access advanced options like robotic da Vinci surgery, HIPEC, and SIRT. Specialized centers like Sheba and Sourasky prioritize multidisciplinary care and clinical trials for complex cases.
Bookimed Expert Insight: Israeli oncology centers like Sheba and Sourasky differentiate themselves through high surgical volumes and specialized training. For example, Dr. Almog Ben Yaacov has performed over 200 HIPEC procedures. This level of specialization often correlates with the 90% success rate reported by Sourasky for oncology treatments. Patients should note that while basic packages for robotic surgery start around $27,300, complex cases requiring HIPEC can range from $52,300 to $68,000 depending on the inclusion of diagnostics and hotel stays.
Patient Consensus: Patients emphasize the need for comprehensive tumor profiling, including genetic and PD-L1 testing, before finalizing a plan. Many note that while standard care is available, explicitly asking about clinical trials can reveal additional options at academic centers.
Patients treating adenocarcinoma in Israel typically stay for 14 to 21 days. Surgical discharge occurs within 3 to 5 days for routine cases. Complex procedures like HIPEC or Whipple surgery require approximately 14 days of hospitalization. Local recovery lasts 1 to 2 weeks before flying home safely.
Bookimed Expert Insight: Israeli oncology centers like Sourasky and Sheba prioritize early mobility to prevent post-op complications. Their `Day 2` physiotherapy protocol specifically targets the respiratory and circulatory systems. This high-intensity approach often allows international patients to transition to hotel-based recovery faster than in European centers. For aggressive cancers, Sheba Medical Center packages even bundle post-discharge hotel stays. This ensures patients remain near their surgical team during the critical first week of outpatient healing.
Patient Consensus: Patients emphasize planning for at least 3 weeks in Israel to handle follow-up tests and imaging. Many suggest packing loose clothing and stool softeners to manage common post-surgical side effects in the local climate.
Israeli hospitals provide comprehensive interpreter services and logistical support for international patients through dedicated departments. Most JCI-accredited facilities offer multilingual staff and personal coordinators. These professionals manage medical translations, visa facilitation, and airport transfers to ensure seamless care for foreign arrivals.
Bookimed Expert Insight: Advanced treatment packages in Israel often bundle high-value logistics directly into the medical cost. For instance, the $27,300 robotic surgery package at Sourasky Medical Center includes clinic transfers. This integration reduces the stress of navigating Tel Aviv for patients undergoing complex oncology procedures.
Patient Consensus: Patients note that while many Israeli doctors speak fluent English, having a dedicated coordinator is essential for navigating hospital bureaucracy. Those visiting Sheba Medical Center often highlight the convenience of having translation and housing support bundled together.